BRPI0513603A - uso de hidroxicarbonato de lantánio e composição farmacêutica - Google Patents

uso de hidroxicarbonato de lantánio e composição farmacêutica

Info

Publication number
BRPI0513603A
BRPI0513603A BRPI0513603-2A BRPI0513603A BRPI0513603A BR PI0513603 A BRPI0513603 A BR PI0513603A BR PI0513603 A BRPI0513603 A BR PI0513603A BR PI0513603 A BRPI0513603 A BR PI0513603A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
ckd
lanthanum hydroxycarbonate
suffering
susceptible
Prior art date
Application number
BRPI0513603-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Josephine Christine Ferdinando
Davido Gilmour
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of BRPI0513603A publication Critical patent/BRPI0513603A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0513603-2A 2004-07-27 2005-07-27 uso de hidroxicarbonato de lantánio e composição farmacêutica BRPI0513603A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59110504P 2004-07-27 2004-07-27
PCT/US2005/026668 WO2006015055A1 (en) 2004-07-27 2005-07-27 Method of treating hyperphosphataemia using lanthanum hydroxycarbonate

Publications (1)

Publication Number Publication Date
BRPI0513603A true BRPI0513603A (pt) 2008-05-13

Family

ID=35787449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513603-2A BRPI0513603A (pt) 2004-07-27 2005-07-27 uso de hidroxicarbonato de lantánio e composição farmacêutica

Country Status (14)

Country Link
US (1) US20060153932A1 (https=)
EP (1) EP1708723A4 (https=)
JP (1) JP4869229B2 (https=)
KR (2) KR20070054191A (https=)
CN (1) CN101018555A (https=)
AU (1) AU2005269362B2 (https=)
BR (1) BRPI0513603A (https=)
CA (1) CA2574450C (https=)
EA (1) EA010980B1 (https=)
MX (1) MX2007001114A (https=)
NO (1) NO20070906L (https=)
NZ (1) NZ552861A (https=)
WO (1) WO2006015055A1 (https=)
ZA (1) ZA200701707B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1852695B1 (en) * 2006-05-05 2011-10-26 Shire International Licensing B.V. Assay for lanthanum hydroxy carbonate
US8961917B2 (en) * 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
GB201501000D0 (en) * 2015-01-21 2015-03-04 Univ Edinburgh Lanthanum thiosulfate and methods of preparation of the same
WO2017072256A1 (en) * 2015-10-27 2017-05-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Nicotinamide for lowering phosphate levels in hyperphosphatemia
KR101880447B1 (ko) * 2015-12-01 2018-07-23 김배용 생리활성물질 복합체, 이의 제조방법 및 이를 포함한 화장료 조성물
KR101684289B1 (ko) 2016-05-17 2016-12-09 한국식품연구원 락토바실러스 sp. KCCM 11826P 균주를 이용한 고인산혈증 예방, 만성 신장질환 치료용 약학조성물 및 건강기능성 식품
US10322409B1 (en) * 2018-03-05 2019-06-18 King Fahd University Of Petroleum And Minerals Low temperature hydrothermal method for the preparation of LaCO3OH nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592082A (en) * 1984-08-10 1986-05-27 The United States Of America As Represented By The United States Department Of Energy Quantitative determination of mineral composition by powder X-ray diffraction
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
US5435986A (en) * 1994-08-30 1995-07-25 Industrial Technology Research Institute Method for preparing high purity aluminum hydroxide
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
DK1389102T3 (da) * 2001-04-23 2011-06-06 Shire Int Licensing Bv Anvendelse af lanthancarbonat til forebyggelse af nyresten
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.

Also Published As

Publication number Publication date
ZA200701707B (en) 2008-10-29
CN101018555A (zh) 2007-08-15
MX2007001114A (es) 2007-07-11
AU2005269362A1 (en) 2006-02-09
CA2574450C (en) 2011-07-19
KR20070054191A (ko) 2007-05-28
NO20070906L (no) 2007-04-23
WO2006015055A1 (en) 2006-02-09
US20060153932A1 (en) 2006-07-13
EP1708723A1 (en) 2006-10-11
EA200700273A1 (ru) 2007-08-31
JP4869229B2 (ja) 2012-02-08
KR101072196B1 (ko) 2011-10-10
EA010980B1 (ru) 2008-12-30
KR20090023743A (ko) 2009-03-05
CA2574450A1 (en) 2006-02-09
JP2008508297A (ja) 2008-03-21
AU2005269362B2 (en) 2010-08-12
NZ552861A (en) 2010-11-26
EP1708723A4 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
BRPI0513603A (pt) uso de hidroxicarbonato de lantánio e composição farmacêutica
NO20082536L (no) Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0507189A (pt) uso combinado de um agonista de glp-1 e compostos de gastrina
AR048888A1 (es) Prevencion de una enfermedad autoinmune
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
ATE353655T1 (de) Myo-inositol hexaphosphat zur topischen verwendung
TW200740452A (en) Therapeutic gastrodia extracts
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
BRPI0509861A (pt) uso de simeticona em pacientes constipados
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
BRPI0615046C1 (pt) uso de um composto
BRPI0504758A (pt) miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
Schmitt et al. Extreme anemia (hemoglobin 1.8 g/dL) secondary to colon cancer
BRPI0616535B8 (pt) uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo
ITMI20032528A1 (it) Uso di cistina o di cisteina per la prevenzione e il
ES2425298B1 (es) Composiciones farmacéuticas para el tratamiento de la metástasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.